<DOC>
	<DOCNO>NCT00771199</DOCNO>
	<brief_summary>The purpose study evaluate safety/tolerability clinical utility low-dose transdermal therapeutic system ( TTS [ medicate adhesive pad place skin deliver timed-release dose medication skin bloodstream ] ) - fentanyl Taiwan participant cancer pain . Secondly , demonstrate dropout rate decrease initiate therapy with12 microgram per hour ( mcg/hr ) instead 25 mcg/h .</brief_summary>
	<brief_title>An Efficacy Safety Study Low-dose Transdermal Therapeutic System ( TTS ) -Fentanyl D-Trans Taiwan Participants With Cancer Pain</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-center ( one hospital medical school team work medical research study ) , single-arm , non-randomized study evaluate efficacy safety low-dose TTS-fentanyl Taiwan participant cancer pain . Eligible participant enrol scheduled return Day 0 , 7 , 14 28 . Participants receive TTS-fentanyl 28 day start dose 12 microgram per hour ( mcg/h ) ( one patch ) . Dose fentanyl increase decrease per Investigator 's discretion maintain participant 's pain score 2 less Brief Pain Inventory ( BPI ) question 6 ( tell much pain right ) . Safety primarily evaluate measure participant 's dropout rate due adverse event . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Participants diagnose cancer ; histologically ( examination tissue specimens microscope ) confirm malignancy ( term diseases abnormal cell divide without control invade nearby tissue ) Participants able communicate effectively study personnel Participants intolerable cancer pain ( pain score great equal [ &gt; = ] 4 ) Participants estimate life expectancy least 30 day Participants give write date informed consent participate study Participants already receive regular treatment strong opioid ( morphinelike synthetic narcotic produce effect drug derive opium poppy [ opiate ] ) , pain enter study Participants already receive tramadol ( narcoticlike pain reliever use treat moderate severe pain ) treatment 200 milligram ( mg ) pain enter study Participants significant abnormality hepatic renal function would , opinion Investigator , prevent participant involvement study Participants significant clinical abnormality central nervous system ( CNS ) , respiratory cardiovascular function , investigator judgment prevents participation study Pregnant lactating female females child bear potential currently practice document , adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Cancer pain</keyword>
	<keyword>Pain</keyword>
	<keyword>Fentanyl</keyword>
	<keyword>Durogesic</keyword>
	<keyword>Cancer</keyword>
	<keyword>Transdermal</keyword>
</DOC>